Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2023 08:30 ET | Source: Vaccinex, Inc.

Vaccinex Announces Initiation of Single-Arm Open Label, Phase Ib/2 Study to Evaluate Pepinemab in Combination with Avelumab as Second Line Combination Immunotherapy for Patients with Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

The study is intended to assess whether pepinemab can reverse the suppressive tumor microenvironment found in PDAC, thereby facilitating the anti-tumor activity of immune checkpoint blockade ...
August 08, 2022 11:00 ET | Source: Vaccinex, Inc.

Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation

Data suggest that pepinemab slows or prevents cognitive decline in Huntington’s Disease (HD) Results highlight the potential for impact on other neurodegenerative and neuroinflammatory diseases...
March 09, 2022 09:00 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer

ROCHESTER, N.Y., March 09, 2022 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and...
November 01, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex to Present at the Virtual Huntington’s Study Group Meeting on November 4-6, 2021

ROCHESTER, N.Y., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative...
September 15, 2021 08:00 ET | Source: Vaccinex, Inc.

Vaccinex CEO, Dr. Maurice Zauderer, Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntington’s Disease Network Meeting

ROCHESTER, N.Y., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease...
September 09, 2016 09:45 ET | Source: Vaccinex, Inc.

Vaccinex, Inc. Announces Continuation of the SIGNAL Clinical Trial

ROCHESTER, N.Y., Sept. 09, 2016 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a clinical-stage biotechnology company engaged in the discovery and development of therapeutic monoclonal antibodies to treat...